Video

Role of Second Generation FLT3 Inhibitors in AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP

Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.

Related Videos
Related Content
Refining CRS and ICANS Management in CAR T-Cell Therapy: Understanding Evolving Diagnostic Criteria and Treatment Strategies
February 15th 2025

Refining CRS and ICANS Management in CAR T-Cell Therapy: Understanding Evolving Diagnostic Criteria and Treatment Strategies

Alana Hippensteele, Lead Editor
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Ensuring Diversity in Clinical Trials Remains Critical
February 13th 2025

Ensuring Diversity in Clinical Trials Remains Critical

Alana Hippensteele, Lead Editor
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
January 29th 2024

Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap

Acute leukemia -- Image credit: Arif Biswas | stock.adobe.com
February 12th 2025

In a Nod to Precision Oncology, the FDA Approves Revumenib

Kevin Le, PharmD, BCOP Ayaa Kobaissi, PharmD Candidate Eugenia Kwon, PharmD Candidate Maidah Farooq Ami Ali, PharmD, BCOP
An enlarged image of fibrous scar tissue, dense collagen network
February 11th 2025

Lactate is a Key Regulator of Immune Escape, Bone Marrow Fibrosis in Myelofibrosis

Luke Halpern, Assistant Editor